Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=funder_divisions
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=funder_divisions", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=funder_divisions", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=funder_divisions", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=funder_divisions" }, "data": [ { "type": "Grant", "id": "9560", "attributes": { "award_id": "2151349", "title": "SBIR Phase II: Facilitating Early Childhood Teacher and Family Engagement During COVID-19", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "SBIR Phase II" ], "program_reference_codes": [], "program_officials": [ { "id": 614, "first_name": "Diane", "last_name": "Hickey", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-07-15", "end_date": "2024-06-30", "award_amount": 964915, "principal_investigator": { "id": 1770, "first_name": "Tammy", "last_name": "Kwan", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 388, "ror": "", "name": "Cognitive ToyBox", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 388, "ror": "", "name": "Cognitive ToyBox", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to ease the burden on early childhood teachers and ensure they have the information needed to support children’s learning. COVID-19 has upended the lives of millions of children and families and disproportionately affected low-income children. The incoming class of preschoolers have increasingly variable levels of development and skills than ever before, and educators need to assess their need and help them to catch up academically. The industry leading tools in early childhood assessment rely solely on observation-based assessment, in which teachers make judgments about a child’s performance based on observations made in the classroom. Observation-based measures have limitations, including time burden, teacher bias, and variability in scoring due to differences in teacher education and training. Observational assessment is especially challenging in the remote context, since teachers were not able to physically monitor children’s development. Even when children are back in the classroom, face masks may shield some of the more subtle cues around learning and development.\n\nThis Small Business Innovation Research (SBIR) Phase II project seeks to ensure an accurate assessment of child development, so that teachers can leverage the data for tailored instruction to help children catch up from the effects of the COVID-19 pandemic. Child assessments are typically observational or direct. This Phase II project collects both observational and direct data, providing an opportunity to compare the data and help teachers understand areas where there may be assessment error due to teacher bias or other factors. At the end of Phase II, it is anticipated that teachers will have access to a self-led teacher training and reliability certification, which may help to ensure a more consistent assessment experience in the classroom. Moreover, educational programs will have access to an assessment quality monitoring dashboard that seeks to highlight differences between observation and game-based assessment scores and provide a path towards reconciliation. Educational programs may be able to customize this technology to fit the needs of English language learners, who are often subject to assessor bias. Finally, teachers may be able to leverage the game-based assessments to understand both academic and “soft” skill development. Overall, the technology may\\provide teachers with a robust child assessment system that helps them to accurately and efficiently assess whole child development.\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15105", "attributes": { "award_id": "2325532", "title": "SBIR Phase II: A Novel Host-Directed Broad-Spectrum Antiviral and Efficient Immunomodulatory Agent Against Coronaviruses: Lead Optimization Studies", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "SBIR Phase II" ], "program_reference_codes": [], "program_officials": [ { "id": 773, "first_name": "Erik", "last_name": "Pierstorff", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": null, "award_amount": 1000000, "principal_investigator": { "id": 31651, "first_name": "Mohammad", "last_name": "Noshi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 356, "ror": "", "name": "Akanocure Pharmaceuticals, Inc.", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact of this Small Business Innovation Research (SBIR) Phase II project stems from the development of a virus agnostic drug that can control the current coronavirus pandemic and potentially future pandemics caused by yet unknown viruses. Since 2020, research has been chasing COVID-19 and its variants by reformulating vaccines and developing more antibodies and antivirals, but the virus has always been ahead, mutating so fast to make those approaches obsolete. Because COVID-19 is not going away, and because a dysregulated (toxic) immune response is not unique to COVID-19, and because viral threats will not stop at COVID-19, a virus and variant agnostic drug that can stop the virus from multiplying, can fix the toxic immune response, is easy to administer in an outpatient or pandemic setting (oral), and can be given early or late in the infection cycle is imperative to get ahead of viral threats. In addition to the positive effect on pandemic preparedness and decreasing the pressure on healthcare systems, such drug can positively impact the economy by preventing the devastating health effects that COVID-19 has on the cardiovascular (heart) and nervous systems, which have led to disability claims sharply rising among the working age group.<br/><br/>The proposed project focuses on the lead optimization of a candidate molecule for oral administration against coronaviruses. SARS-CoV-2 infections cause hyperinflammation and autoimmunity leading to multi-organ damage even with mild infections. The damage is cumulative and repeat infections increase the risk of long COVID. These clinical manifestations are due to persistent/chronic infections and dysregulated immune responses. An ideal treatment would not only suppress viral replication but would also restore the immune system homeostasis and healthy immune response. In Phase I, a molecule was designed, synthesized, and shown to be an efficient immunomodulatory and broad-spectrum antiviral. This molecule targets the host rather than the virus which decreases the chances of resistance and makes it virus/variant agnostic, unlike vaccines and direct-acting antivirals. In Phase II, the technical objectives focus on design, synthesis, and testing of analogs with improved drug-like properties for oral administration. Those analogs will be evaluated against several SARS-CoV-2 variants in-vitro, subjected to in-vitro ADME studies, and assessed for their effect on the production of immune mediators in virus-infected cells. The analog with the best profile will advance to in-vivo studies to test its pharmacokinetic and toxicological properties in mice, as well as its efficacy and immune modulations activity in virus-infected animal rodents.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15127", "attributes": { "award_id": "2335297", "title": "SBIR Phase II: A Natural Product Drug Discovery Platform Based on High-Throughput Elicitor Screening (HiTES)", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "SBIR Phase II" ], "program_reference_codes": [], "program_officials": [ { "id": 773, "first_name": "Erik", "last_name": "Pierstorff", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": null, "award_amount": 999109, "principal_investigator": { "id": 31685, "first_name": "Brett", "last_name": "Covington", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2511, "ror": "", "name": "CRYPTYX BIOSCIENCE, INC.", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact of this Small Business Innovation Research (SBIR) Phase II project stems from the identification and advancement of novel compounds with therapeutic or commercial potential from natural sources. Microbial natural products have been a traditional source of FDA-approved drugs and drug leads, but discovery efforts are hampered by the fact that 80-90% of natural products that a given microbe can produce are cryptic, meaning they are not produced under standard laboratory conditions. By turning on >90% of biosynthetic pathways and unearthing these cryptic natural products, the technology developed by this project may enable discovery of novel microbial compounds, giving researchers access to urgently needed new therapeutics while making the whole process faster and more affordable than extant methodologies. This approach has the potential to usher in a new era of drug discovery, strengthening the U.S. pharmaceutical industry and economy. New antibiotics will help to combat the alarming rise of multidrug-resistant bacteria. Other pharmaceuticals, like anticancer agents, immunosuppressants and antivirals will contribute to improved health outcomes for those with cancer, autoimmune diseases, and viral infections. Of relevance to national defense and security, this technology could be used to rapidly identify novel therapeutics and bioactive compounds against emerging pandemic diseases and potential agents of bioterrorism.<br/><br/>The proposed project seeks to develop novel antibiotics and anticancer agents using a revolutionary drug discovery platform. While natural products are the most promising source of new drugs, conventional methods of discovery fail to unlock the full metabolomic potential of the organisms that produce them, require challenging culture conditions, and are plagued with high rates of rediscovery. Phase I demonstrated proof-of-concept for a comprehensive drug discovery pipeline focusing on cryptic microbial natural products. The platform challenges bacteria with a library of small molecules, some of which mimic the bacteria’s competitive native environment, thus activating otherwise silent biosynthetic pathways. It is flexible and allows for chemistry-first or built-in bioactivity screening as the first step in the pipeline. The focus of Phase II is to further validate molecules discovered in Phase I and demonstrate the ability of the platform to uncover compounds with suitable drug-like properties. The project will also scale up the technology to establish a large library of ~2,000 novel natural products to be screened against various indications, and expand the utility for the identification of anticancer agents. Successful completion of this project will further validate and expand the utility of the platform for drug and bioactive molecule discovery.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15141", "attributes": { "award_id": "2423051", "title": "SBIR Phase II: Development of an End-to-End Solution for High-Volume Water Microbiological Testing", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "SBIR Phase II" ], "program_reference_codes": [], "program_officials": [ { "id": 936, "first_name": "Henry", "last_name": "Ahn", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-15", "end_date": null, "award_amount": 995600, "principal_investigator": { "id": 5090, "first_name": "Abdennour", "last_name": "Abbas", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 227, "ror": "", "name": "University of Minnesota-Twin Cities", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1982, "ror": "", "name": "FRONTLINE BIOTECHNOLOGIES INC.", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to enhance public health and safety through advanced water microbiological testing technologies. This project's innovation enables the early detection of pandemics by identifying waterborne viruses such as SARS-CoV-2 which causes COVID-19, and norovirus, which is notorious for causing gastroenteritis, potentially weeks before outbreaks manifest. Such early detection is vital for policymakers, allowing more effective intervention strategies and reducing both human casualties and healthcare costs. Moreover, the technology promises to improve the safety of drinking water, particularly important as many states increasingly turn to recycling wastewater due to drought. This could decrease the incidence of waterborne illnesses, which currently affect millions and cost the U.S. healthcare system billions annually. Additionally, the innovation facilitates more accessible and efficient water testing in remote and underserved communities by reducing costs and processing times, supporting healthcare equity. Finally, this new approach not only promises to transform drinking water safety monitoring practices and wastewater-based pandemic surveillance but also drives the implementation of new water quality standards and regulatory frameworks, aligning with the Best Available Technology practices.<br/><br/>This Small Business Innovation Research (SBIR) Phase II project addresses significant gaps in water microbiological testing. Monitoring the presence of viruses such coronavirus and norovirus in water is crucial for pandemic surveillance and drinking water safety. Waterborne viruses are present in low concentrations and their detection requires the analysis of large sample volumes. However, current tools are designed for small volumes, resulting in low sensitivity and high variability in testing results. The goal of this project is to develop a comprehensive technological solution to enhance the reliability and standardization of wastewater epidemiology and drinking water testing, a pressing need identified by health agencies to improve data quality and comparability. The current effort focuses on developing a scalable platform that integrates a novel filtration cartridge and reagent kit, capable of processing up to two liters of water in less than five minutes. This capability enhances the yield and purity of viral nucleic acids and improves the detection limit by two orders of magnitude, enhancing accuracy and reducing false positives. By improving our ability to monitor pathogen spread through community water systems, this project is expected to enhance pandemic preparedness and drinking water safety and facilitate more effective public health interventions.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14616", "attributes": { "award_id": "2304278", "title": "SBIR Phase II: An immersive virtual reality platform for remote physical therapy and monitoring", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "SBIR Phase II" ], "program_reference_codes": [], "program_officials": [ { "id": 806, "first_name": "Alastair", "last_name": "Monk", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-05-01", "end_date": null, "award_amount": 1000000, "principal_investigator": { "id": 31298, "first_name": "Aviv", "last_name": "Elor", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2483, "ror": "", "name": "IMMERGO LLC", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II<br/>project concerns greater affordability, accessibility, and accuracy of physical therapy for patients and<br/>therapists. The product to be commercialized will contribute to developing innovation around immersive<br/>telehealth experiences, exploring the future of work for physical rehabilitation in the metaverse,<br/>establishing standards in embodied telehealth, and grounding novel scientific research methods within VR<br/>for healthcare from a California-based startup with the goal of increasing access to care. Establishing a<br/>remote immersive virtual platform will provide a means for in-patient success metrics and full-body virtual<br/>guidance. Patient throughput potentially could be doubled through remote visits in virtual environments<br/>and automated physical health documentation. The platform will be designed with accessibility in mind<br/>with patients from \"medical deserts,\" where patient care is significantly limited by hospital capacity,<br/>physical distance, doctors per population, and cost. Remote physical rehabilitation tools and predictive<br/>physical therapy analytics will benefit patients without adequate insurance coverage. This technology<br/>could lower hospital visits, enable clinics to remain open during future pandemic periods, decrease costs<br/>for patients and clinics alike, and begin detecting physical health needs earlier to help manage the pace<br/>of recovery.<br/><br/>The proposed project aims to expand a novel physical rehabilitation telehealth solution through the<br/>continued research of an instrumented and gamified immersive virtual reality platform for physical therapy<br/>and healthcare monitoring. This technology addresses the shortcomings of widely used telehealth platforms (often videoconferencing) where therapists find it difficult to perform common evaluations<br/>such as movement abilities and balance coordination tests. The solution will expand upon an embodied<br/>telehealth platform with 3D virtual avatars and predictive AI tools to assess user biomechanics in real-time<br/>extending to full-body assessment while providing normative assessment metrics, creating a goal<br/>standard for remote physical therapy care. The development method will continue to utilize user-centered<br/>design with a panel of therapists to ensure accessibility and usability of the prototype systems by their<br/>relevant stakeholders. Such research will incorporate predictive biomechanical analysis to increase the<br/>reliability and repeatability of physical therapy measures and exercise programs for remote monitoring<br/>at the clinic or the patient’s home. Iterative prototyping with user experience will be conducted to<br/>establish in-patient success metrics and full-body virtual assessment. This innovation will enable greater<br/>affordability, usability, and effectiveness of physical therapy for patients and therapists.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14656", "attributes": { "award_id": "2313338", "title": "SBIR Phase II: Design and production of a next generation vaccine to prevent COVID", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "SBIR Phase II" ], "program_reference_codes": [], "program_officials": [ { "id": 773, "first_name": "Erik", "last_name": "Pierstorff", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-03-15", "end_date": null, "award_amount": 997689, "principal_investigator": { "id": 31355, "first_name": "Peter", "last_name": "Leonardi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 346, "ror": "", "name": "OMNICYTE, LLC", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact of this Small Business Innovation Research (SBIR) Phase II project is to develop a next-generation COVID-19 vaccine that addresses the weaknesses of the current vaccines. While the current COVID-19 vaccines have saved countless lives and have allowed our society to get back to normal, they have their weaknesses. The boosters are sometimes not effective, and when they are, they have short-lived efficacy and they can have mild to severe side effects. These weaknesses not only put individuals at risk of getting sick with COVID or the side effects, but those weaknesses also compromise confidence in the vaccine, which affects compliance. The proposed project promises to produce a next-generation vaccine that has better efficacy and significantly reduced side effects, as well as increased duration of effectiveness. This could pave the way for an effective annual administration schedule of the vaccine booster that addresses new strains, much like the seasonal influenza vaccine. <br/><br/>The proposed project intends to produce a next-generation vaccine that can renew confidence in vaccinating to prevent COVID-19. The project's objectives are to show that the vaccine candidate can not only create an immune response that can stop the spread of the virus but also kill the virus. Additionally, it is hoped that the project will show that the vaccine is safer than the current vaccines and that it promotes an immune response that lasts significantly longer than current vaccines. This will be accomplished by testing the vaccine in a Hamster model that simulates the human respiratory system well. Not only will efficacy be tested, but the longevity of the immune response will also be tested. As an additional objective of the study, the route of administration will be examined. The vaccine's effectiveness will be compared by administering it either through injection, nasal administration, or a microneedle patch.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14557", "attributes": { "award_id": "2127355", "title": "SBIR Phase II: Automation of a Novel Low Cost Aluminum Additive Manufacturing Method", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "SBIR Phase II" ], "program_reference_codes": [], "program_officials": [ { "id": 28721, "first_name": "Ela", "last_name": "Mirowski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-12-01", "end_date": null, "award_amount": 1000000, "principal_investigator": { "id": 31203, "first_name": "Alison", "last_name": "Forsyth", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2476, "ror": "", "name": "ALLOY ENTERPRISES INC.", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact of this Small Business Innovation Research (SBIR) Phase II project is to improve aluminum additive manufacturing (AM). AM remains of great interest to original equipment manufacturers (OEMs) for its promise of producing parts on-demand; however, low throughput and high costs of aluminum powder limit adoption. The proposed technology produces consistent parts with established alloys, such as the commonly used 6061 aluminum alloy. These alloys have immediate commercial applications in servicing legacy equipment parts and for making vehicles more lightweight, thus improving efficiency and reducing carbon emissions. Further, this technology can support low-to-medium production volumes, allowing smaller manufacturers to take advantage of AM as a platform for innovation. <br/><br/>This Small Business Innovation Research (SBIR) Phase II project aims to deliver on-demand production at the unit cost of casting. The research objectives will optimize core processes for a novel aluminum metal-to-metal sheet bonding technology, and achieve process automation. This technology provides on-demand parts with high strength wrought alloy properties and the capability to design innovative components that could not be previously considered with traditional manufacturing processes. The anticipated results are improved material and mechanical properties, system integration, and increased throughput and part complexity.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "13292", "attributes": { "award_id": "2136497", "title": "SBIR Phase II: A smart wearable platform for remote respiratory monitoring", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "SBIR Phase II" ], "program_reference_codes": [], "program_officials": [ { "id": 806, "first_name": "Alastair", "last_name": "Monk", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-03-01", "end_date": null, "award_amount": 990118, "principal_investigator": { "id": 4361, "first_name": "Jason", "last_name": "Kroh", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 642, "ror": "", "name": "Strados Labs, Inc.", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 642, "ror": "", "name": "Strados Labs, Inc.", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to complete the development of a remote electronic stethoscope platform to help physicians and clinicians remotely diagnose and monitor a patient’s respiratory status quickly, conveniently, and objectively in an at-home setting. This technology will not only improve the quality of care for patients, but also enable widespread use of safely-monitored, home-based pulmonary rehabilitation, which will contribute to a reduction in patient morbidity and mortality related to respiratory diseases. The platform will also potentially enable a large collection of respiratory physiological data, providing a valuable database for clinical and scientific research as well as a framework for the use of artificial intelligence tools that may improve respiratory care. <br/><br/>The proposed project addresses the challenge of telemonitoring the respiratory condition of patients suffering from asthma and other pulmonary diseases, such as emphysema and chronic bronchitis. The current standard of care relies on intermittent monitoring via stethoscope by a trained healthcare professional, which raises significant inter-user variability in the assessment and classification of lung sounds. The proposed project will advance noise reduction, design-to-cost, and design-for-manufacturing improvements, upgrading the backend data annotation and analysis system to ensure system scalability and validating the system usability and safety with substantial and relevant patient testing. The final smart wearable stethoscope platform will enable development of predictive algorithms that offer prolonged monitoring and recording of lung acoustic signals for improved care.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "12429", "attributes": { "award_id": "2151628", "title": "SBIR Phase II: Rapid disinfection using compact plasma reactors", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "SBIR Phase II" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-10-01", "end_date": null, "award_amount": 0, "principal_investigator": { "id": 28378, "first_name": "Justin", "last_name": "Kosky", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 616, "ror": "", "name": "SurfPlasma, Inc.", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project addresses the societal need for a non-thermal, economical, and efficient solution for sterilizing deadly pathogens that are common in medical facilities and everyday living spaces. The commercial opportunity lies in developing a non-thermal, portable, safe, and economical sterilization device for materials contaminated with virus, bacteria, and fungi. The proposed technology will be used in areas that are lacking in current state-of-the-art sterilization technologies. It operates at low temperature, necessary for temperature-sensitive equipment, is ecofriendly, has high throughput, requires little maintenance, and includes an inbuilt mixing system for the sterilization of complex surface geometries. Applications include sterilizing personal protective equipment (PPE), surgical tools, medical devices, food, beverages, etc. from harmful pathogens. The addressable market consists of healthcare facilities, medical device companies, and food and beverage companies. The major impact will be in crowded facilities and community settings where rapid disinfection of objects is required. Additionally, the technology can be integrated with existing systems like refrigeration units. The technology is expected to save lives by preventing hospital-acquired infections, the further spread of COVID-19, and possible future outbreaks.This SBIR Phase II project proposes a sterilization device that operate at low temperatures, works with complex geometries, and is low energy and low cost. These areas are not currently addressed by one single, state-of-the-art sterilization technology. The solution is based on an active plasma module (APM). Previously, research established APM efficacy against SARS CoV-2 and its surrogate on metal, plastic, and fabric, and the required operating conditions (exposure times, ozone requirements, and power) to achieve sterilization. The objectives in this project include prototype development with (i) efficacy tests against BioSafety Level (BSL)-2 and -3 pathogens, (ii) cycle times, ozone requirements, and power demands, (iii) a practical ozone removal system to meet safety limits, (iv) material compatibility data, and (v) a user-friendly control interface. The team will also examine APM quality control, the ability to meet required product specifications, and management of the reverse-engineering threat. Successful Phase II completion will result in a market-ready prototype with sterilization data against various pathogens and product specifications required for customer adoption. The project will advance research on power efficient ozone sterilization.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "12463", "attributes": { "award_id": "2317290", "title": "SBIR Phase II: Analog front end (AFE) platform for lightweight, long-term, cortical monitoring", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "SBIR Phase II" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-09-01", "end_date": null, "award_amount": 0, "principal_investigator": { "id": 28402, "first_name": "Mark", "last_name": "Myers", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2107, "ror": "", "name": "NEURODYNE, INC.", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project provides next generation ambulatory seizure data acquisition. The advent of mobile health advances during the COVID-19 health crisis have enabled new innovations to be considered. This effort provides a framework for the next line of remote neurological data acquisition capabilities for the implementation of military helmet designs that detect battlefield traumatic brain injuries, football helmet designs that detect sports-related brain injuries, caps for first responder teams that detect trauma, at-home monitoring headsets for remote migraine assessment, etc. A complete analogue front end (AFE) will be developed in order to provide digitized electroencephalograph (EEG) signals to the downstream stages. The project will have a major impact in several areas, namely, wearable bio-devices, data fusion, and neurological data extraction and visualization of complex biological systems. This device can be utilized for first responders at the scene of neurological trauma such as emergency medical technicians, battle front medical areas, and sports related events.This Small Business Innovation Research Phase II project will provide a robust mobile device that can be worn in an at-home setting for remote neurological monitoring. The solution will remove noisy artifacts from the electroencephalograph signal in order to perform neurological diagnoses and provide neurological reporting to the neurologist as an aid to quantify the patient’s seizure instances. The analogue front end (AFE) provides the foundation for a portable electroencephalograph (EEG) device for neurological data acquisition for the clinical, academic, and research communities. The ambulatory seizure monitoring device will enable an end-to-end system for robust, lightweight, data transmission to a cloud service, which will generate reports for the physician to analyze a patient neurological data for treatment. This system will extend the current rise of health devices into the complex environment of neurological states, as well as the eventual development of neuro-analytics.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1419, "count": 14184 } } }